<DOC>
	<DOCNO>NCT01546909</DOCNO>
	<brief_summary>PRIMARY OBJECTIVES - To describe 11 13-year-old child previously vaccinate either REVAXIS DT Polio 6 year age antibody persistence diphtheria , tetanus , poliovirus type 1 , 2 3 - To describe one month booster dose TETRAVAC-ACELLULAIRE immune response diphtheria , tetanus , poliovirus type 1 , 2 3 SECONDARY OBJECTIVES - To describe parameter antibody persistence diphtheria , tetanus poliomyelitis antigens - To describe parameter immune response diphtheria , tetanus poliomyelitis antigens one month booster dose TETRAVAC-ACELLULAIRE - To describe safety profile booster dose TETRAVAC-ACELLULAIRE</brief_summary>
	<brief_title>Antibody Persistence REVAXIS DT Polio Immune Response TETRAVAC-ACELLULAIRE</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Healthy child 11 13 year age previously vaccinate Study F05TdI301 Immunization diphtheria , tetanus , pertussis and/or poliomyelitis beyond Study F05TdI301 Previous clinical bacteriological diagnosis diphtheria , tetanus , pertussis poliomyelitis Known suspect immune dysfunction Receipt medication / vaccination may interfere study assessment Known true hypersensitivity vaccine component vaccine contain substance Known personal history encephalopathy , seizure disorder progressive , evolve unstable neurological condition Thrombocytopenia coagulation disorder would contraindicate intramuscular injection Any medical condition might interfere evaluation study objective Febrile illness</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>